Go Pro
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
$0.63
-1.9%		$0.73
$0.59
▼
$3.15
$27.32M0.8831,810 shs45,210 shs
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
$3.14
+3.6%		$3.07
$2.77
▼
$12.15
$26.18M0.2696,300 shs2,189 shs
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
$1.66
+3.4%		$4.30
$1.58
▼
$20.99
$28.02M1.16121,241 shs14,231 shs
Sonnet BioTherapeutics Holdings, Inc. stock logo
SONN
Sonnet BioTherapeutics
$1.02
-67.3%		$2.37
$1.08
▼
$19.30
$7.18M1.482.09 million shs10.08 million shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
+4.73%+0.30%-15.82%-32.64%-42.87%
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
-0.33%-7.90%-3.19%-0.66%+3.06%
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
+3.44%-7.02%-47.63%-64.79%-85.82%
Sonnet BioTherapeutics Holdings, Inc. stock logo
SONN
Sonnet BioTherapeutics
0.00%0.00%0.00%0.00%-84.34%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
$0.63
-1.9%		$0.73
$0.59
▼
$3.15
$27.32M0.8831,810 shs45,210 shs
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
$3.14
+3.6%		$3.07
$2.77
▼
$12.15
$26.18M0.2696,300 shs2,189 shs
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
$1.66
+3.4%		$4.30
$1.58
▼
$20.99
$28.02M1.16121,241 shs14,231 shs
Sonnet BioTherapeutics Holdings, Inc. stock logo
SONN
Sonnet BioTherapeutics
$1.02
-67.3%		$2.37
$1.08
▼
$19.30
$7.18M1.482.09 million shs10.08 million shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
+4.73%+0.30%-15.82%-32.64%-42.87%
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
-0.33%-7.90%-3.19%-0.66%+3.06%
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
+3.44%-7.02%-47.63%-64.79%-85.82%
Sonnet BioTherapeutics Holdings, Inc. stock logo
SONN
Sonnet BioTherapeutics
0.00%0.00%0.00%0.00%-84.34%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
2.00
Hold$8.001,150.20% Upside
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
2.67
Moderate Buy$11.00263.04% Upside
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
1.00
SellN/AN/A
Sonnet BioTherapeutics Holdings, Inc. stock logo
SONN
Sonnet BioTherapeutics
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest SONN, RNAZ, ESLA, and EVAX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/8/2026
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/25/2026
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/11/2026
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/21/2026
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/17/2026
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/9/2026
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
(Data available from 9/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
N/AN/AN/AN/A($0.27) per shareN/A
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
$7.53M3.36N/AN/A$2.04 per share1.49
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
N/AN/AN/AN/A$11.27 per shareN/A
Sonnet BioTherapeutics Holdings, Inc. stock logo
SONN
Sonnet BioTherapeutics
$1M7.18N/AN/A($0.71) per share-1.43
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
-$13.06M-$0.24N/AN/AN/AN/AN/A-328.72%12/2/2026 (Estimated)
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
-$7.71M-$1.21N/AN/AN/AN/A-61.43%-34.23%11/5/2026 (Estimated)
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
-$34.66M-$52.37N/AN/AN/AN/A-875.35%-37.46%11/18/2026 (Estimated)
Sonnet BioTherapeutics Holdings, Inc. stock logo
SONN
Sonnet BioTherapeutics
-$7.44M-$8.05N/AN/AN/AN/A-4,646.10%-342.21%N/A

Latest SONN, RNAZ, ESLA, and EVAX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
N/A-$7.17N/A-$7.17N/AN/A
8/13/2026Q2 2026
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
-$0.09-$0.05+$0.04-$0.05N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
N/AN/AN/AN/AN/A
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
N/AN/AN/AN/AN/A
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
N/AN/AN/AN/AN/A
Sonnet BioTherapeutics Holdings, Inc. stock logo
SONN
Sonnet BioTherapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
N/A
0.20
0.20
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
0.69
5.06
5.06
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
N/A
1.97
1.97
Sonnet BioTherapeutics Holdings, Inc. stock logo
SONN
Sonnet BioTherapeutics
N/A
0.26
0.26

Institutional Ownership

CompanyInstitutional Ownership
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
0.35%
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
11.04%
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
N/A
Sonnet BioTherapeutics Holdings, Inc. stock logo
SONN
Sonnet BioTherapeutics
9.45%

Insider Ownership

CompanyInsider Ownership
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
5.80%
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
41.64%
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
0.10%
Sonnet BioTherapeutics Holdings, Inc. stock logo
SONN
Sonnet BioTherapeutics
8.48%
CompanyEmployeesShares OutstandingFree FloatOptionable
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
N/A43.50 million40.98 millionNot Optionable
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
608.34 million4.87 millionNo Data
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
916.93 million16.91 millionNot Optionable
Sonnet BioTherapeutics Holdings, Inc. stock logo
SONN
Sonnet BioTherapeutics
107.08 million6.48 millionNot Optionable

Recent News About These Companies

Hyperliquid Strategies Wins Approval to Pursue $1B Offering and HYPE Token Treasury
December 3, 2025  |  crypto-news-flash.comC
HYPE News: Hyperliquid DAT Approval Lifts HYPE Token Nearly 10%
December 3, 2025  |  livebitcoinnews.comL
Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
December 2, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/12/02/3198438/0/en/hyperliquid-strategies-inc-and-sonnet-biotherapeutics-holdings-inc-announce-closing-of-business-combination.html
Sonnet BioTherapeutics stockholders approve Hyperliquid Strategies combination
December 2, 2025  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/sonnet-biotherapeutics-stockholders-approve-hyperliquid-strategies-combination/ar-AA1RzzqZ
Sonnet shareholders approve Hyperliquid merger to launch HYPE-focused crypto treasury
December 2, 2025  |  cryptobriefing.comC
HYPE Jumps 10% as Hyperliquid Treasury Firm Sonnet Secures Merger Approval
December 2, 2025  |  coingape.comC
Sonnet BioTherapeutics Holdings, Inc. Announces Stockholder Approval of Proposed Business Combination with Hyperliquid Strategies Inc
December 2, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/sonnet-biotherapeutics-holdings-inc-announces-141700887.html
Sonnet delays vote on Hyperliquid merger to launch $1B HYPE-focused treasury firm
November 18, 2025  |  cryptobriefing.comC
Sonnet BioTherapeutics Holdings, Inc. Announces Adjournment of Special Meeting
November 18, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/11/18/3190081/0/en/sonnet-biotherapeutics-holdings-inc-announces-adjournment-of-special-meeting.html
Sonnet BioTherapeutics Announces Special Meeting for Business Combination Vote
October 29, 2025  |  msn.comhttps://www.msn.com/en-us/money/topstocks/sonnet-biotherapeutics-announces-special-meeting-for-business-combination-vote/ar-AA1Piyw9
Hyperliquid Price Surges as $1B Fundraising and IPO Plans Boost HYPE
October 25, 2025  |  thecurrencyanalytics.comT
Hyperliquid Strategies Aims to Raise $1 Billion to Expand HYPE Token Treasury
October 24, 2025  |  thecurrencyanalytics.comT
Hyperliquid Token Defies Market Slump as Institutional Capital Flows In
October 24, 2025  |  thecurrencyanalytics.comT
Hyperliquid Price Soars 12% As Hyperliquid Strategies Plans $1B Raise For HYPE Treasury
October 23, 2025  |  insidebitcoins.comI
Hyperliquid's $1B Power Play: HYPE Token Surge and Bitcoin Whale Frenzy
October 23, 2025  |  econotimes.comhttps://www.econotimes.com/Hyperliquids-1B-Power-Play-HYPE-Token-Surge-and-Bitcoin-Whale-Frenzy-1723998
Hyperliquid Strategies Files $1B IPO to Build HYPE Treasury
October 23, 2025  |  financefeeds.comF
Hyperliquid’s HYPE soars as Wall Street backs $888 million merger
October 23, 2025  |  msn.comhttps://www.msn.com/en-us/news/other/hype-token-surges-after-888-million-wall-street-backed-merger/ar-AA1P1A4u
Hyperliquid Wants $1B to Power Its Next HYPE Token Expansion
October 23, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/hyperliquid-wants-1b-power-next-080217130.html
Sonnet BioTherapeutics, Spanios collaborate on non-clinical study of SON-1010
October 16, 2025  |  msn.comhttps://www.msn.com/en-us/money/other/sonnet-biotherapeutics-spanios-collaborate-on-non-clinical-study-of-son-1010/ar-AA1OxdyU
Evaluation of SON-1010 Using a Patient-Derived Tumoroid Platform to Support an Ongoing Phase 1 Study in Patients with Sarcoma
October 15, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/10/15/3167271/0/en/evaluation-of-son-1010-using-a-patient-derived-tumoroid-platform-to-support-an-ongoing-phase-1-study-in-patients-with-sarcoma.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
A gold futuristic electric concept car parked on a street with a city skyline and capitol dome at dusk.
Tesla's Cybercab Launch Could Reshape Margins for Uber and Lyft
By Jeffrey Neal Johnson | August 19, 2026
A Tesla concept vehicle with illuminated front light bar drives on a road against a city skyline at dusk.
Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected
By Sam Quirke | September 8, 2026
Gold-colored concept electric vehicle with a smooth, minimalist body parked outdoors near a building and tree.
Ride-Share Reckoning: Tesla Drives Into Uber's Lane
By Jeffrey Neal Johnson | September 7, 2026
Red Tesla vehicle parked beside a building displaying the Tesla logo, with mountains in the background.
Can Tesla’s Flying Roadster Distract From Its Real Risks?
By Sam Quirke | August 26, 2026
A Zoox autonomous vehicle drives on a city street in front of an Amazon office building with logo.
Amazon’s Zoox Push Tests Tesla’s Robotaxi Premium as Waymo Widens Its Lead
By Sam Quirke | August 29, 2026
Estrella Immunopharma stock logo

Estrella Immunopharma NASDAQ:ESLA

$0.63 -0.01 (-1.86%)
As of 09:46 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

Evaxion A/S stock logo

Evaxion A/S NASDAQ:EVAX

$3.14 +0.11 (+3.60%)
As of 09:51 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.

TransCode Therapeutics stock logo

TransCode Therapeutics NASDAQ:RNAZ

$1.66 +0.06 (+3.44%)
As of 09:53 AM Eastern
This is a fair market value price provided by Massive. Learn more.

TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.

Sonnet BioTherapeutics stock logo

Sonnet BioTherapeutics NASDAQ:SONN

Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas